| EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease A Heidenreich, J Bellmunt, M Bolla, S Joniau, M Mason, V Matveev, ... European urology 59 (1), 61-71, 2011 | 5566* | 2011 |
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm … JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ... The Lancet 387 (10031), 1909-1920, 2016 | 3850 | 2016 |
| EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent N Mottet, J Bellmunt, M Bolla, E Briers, MG Cumberbatch, M De Santis, ... European urology 71 (4), 618-629, 2017 | 3776 | 2017 |
| Pembrolizumab as second-line therapy for advanced urothelial carcinoma J Bellmunt, R De Wit, DJ Vaughn, Y Fradet, JL Lee, L Fong, NJ Vogelzang, ... New England Journal of Medicine 376 (11), 1015-1026, 2017 | 3405 | 2017 |
| Early childhood development coming of age: science through the life course MM Black, SP Walker, LCH Fernald, CT Andersen, AM DiGirolamo, C Lu, ... The Lancet 389 (10064), 77-90, 2017 | 3083 | 2017 |
| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer T Powles, JP Eder, GD Fine, FS Braiteh, Y Loriot, C Cruz, J Bellmunt, ... Nature 515 (7528), 558-562, 2014 | 2671 | 2014 |
| EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013 A Heidenreich, PJ Bastian, J Bellmunt, M Bolla, S Joniau, T van der Kwast, ... European urology 65 (1), 124-137, 2014 | 2483 | 2014 |
| Comprehensive molecular characterization of muscle-invasive bladder cancer AG Robertson, J Kim, H Al-Ahmadie, J Bellmunt, G Guo, AD Cherniack, ... Cell 171 (3), 540-556. e25, 2017 | 2408 | 2017 |
| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 2207 | 2017 |
| EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer P Cornford, J Bellmunt, M Bolla, E Briers, M De Santis, T Gross, AM Henry, ... European urology 71 (4), 630-642, 2017 | 1621 | 2017 |
| First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase … AV Balar, D Castellano, PH O'Donnell, P Grivas, J Vuky, T Powles, ... The Lancet Oncology 18 (11), 1483-1492, 2017 | 1320 | 2017 |
| Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ... New England Journal of Medicine 383 (13), 1218-1230, 2020 | 1184 | 2020 |
| A consensus molecular classification of muscle-invasive bladder cancer A Kamoun, A de Reynies, Y Allory, G Sjödahl, AG Robertson, R Seiler, ... European urology 77 (4), 420-433, 2020 | 1070 | 2020 |
| Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival B Escudier, J Bellmunt, S Négrier, E Bajetta, B Melichar, S Bracarda, ... Journal of Clinical Oncology 28 (13), 2144-2150, 2010 | 1065 | 2010 |
| Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell … J Bellmunt, C Théodore, T Demkov, B Komyakov, L Sengelov, ... Journal of Clinical Oncology 27 (27), 4454-4461, 2009 | 878 | 2009 |
| Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with … P Dombernowsky, I Smith, G Falkson, R Leonard, L Panasci, J Bellmunt, ... Journal of clinical oncology 16 (2), 453-461, 1998 | 822 | 1998 |
| Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin … M De Santis, J Bellmunt, G Mead, JM Kerst, M Leahy, P Maroto, T Gil, ... Journal of clinical oncology 30 (2), 191-199, 2012 | 782 | 2012 |
| EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer N Mottet, J Bellmunt, M Bolla, S Joniau, M Mason, V Matveev, HP Schmid, ... Actas Urológicas Españolas (English Edition) 35 (10), 565-579, 2011 | 745 | 2011 |
| Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy MD Galsky, NM Hahn, J Rosenberg, G Sonpavde, T Hutson, WK Oh, ... Journal of clinical oncology 29 (17), 2432-2438, 2011 | 658 | 2011 |
| Guidelines on prostate cancer N Mottet, J Bellmunt, E Briers, RCN Van den Bergh, M Bolla, ... European Association of Urology 56, e137, 2015 | 616 | 2015 |
